18th European Biosimilars Congress 2025

Topics

• Chemical and Analytical Strategies for Biosimilars
• Current Challenges in Developing Biosimilars
• Biological Medicine
• Intellectual Property Rights
• Innovative Clinical Approach in Biosimilars
• Emerging Biosimilars in Therapeutics
• Biosimilars Development in Markets
• Regulatory Updates on Biosimilars
• Biopharmaceutical Informatics
• Biosimilars Approval to Biogenerics in Clinical Practice
• BCS and IVIVC Based Biowaivers
• Consequences of Brexit on Biosimilars
• Challenges in Biosimilars Pharmacovigilance
• Biosimilars Market and Cost Analysis
• Formulation Strategies for Follow-on Biologics
• Legal Issues and BPCI Act
• Biosimilars Research Pipeline
• Current Agency Expectations for Approval for Biosimilars
• Drug Delivery and Development
• Globalization of Biosimilars
• USFDA Approved Biosimilars
• Monoclonal Antibody Biosimilars

Who should Attend

Heads of Department, Directors, Scientists and Managers of: Product Patrimony, Laboratory Bioanalytics, Biopharmarceutical Technology, Global Marketing & Access, Regulatory Affairs, Strategy, Biopharmaceuticals, Operations, Biotechnical, Business Development and Documentation.